Neogenomics Inc

NEO remains in a Stage 2 advancing regime with a bullish medium-term structure driven by an active Parabola pattern, yet price action is extremely overbought and extended above rising EMAs, indicating near-term exhaustion. We will defer new entries and stalk for a pullback into the rising 9/21 EMA support zone before engaging.

• ↑Q1 2026 revenue of $186.7M (+11% YoY) beat guidance
• ↑Clinical revenue $171.2M (+14% YoY) driven by oncology testing
• ↓Non-clinical revenue down 26% on reduced pharma spending